SCYNEXIS Future Growth
Future criteria checks 5/6
SCYNEXIS is forecast to grow earnings and revenue by 48.7% and 30.8% per annum respectively while EPS is expected to grow by 49.2% per annum.
Key information
48.7%
Earnings growth rate
49.2%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 30.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 111 | 65 | 17 | 40 | 4 |
| 12/31/2025 | 53 | 8 | N/A | 12 | 4 |
| 12/31/2024 | 10 | -22 | N/A | -14 | 4 |
| 9/30/2024 | 9 | -36 | -22 | -22 | N/A |
| 6/30/2024 | 10 | -35 | -10 | -10 | N/A |
| 3/31/2024 | 140 | 101 | 75 | 75 | N/A |
| 12/31/2023 | 140 | 67 | 60 | 60 | N/A |
| 9/30/2023 | 136 | 72 | 45 | 45 | N/A |
| 6/30/2023 | 136 | 44 | 10 | 10 | N/A |
| 3/31/2023 | 6 | -91 | -83 | -83 | N/A |
| 12/31/2022 | 5 | -63 | -80 | -80 | N/A |
| 9/30/2022 | 4 | -78 | -83 | -83 | N/A |
| 6/30/2022 | 3 | -49 | -78 | -77 | N/A |
| 3/31/2022 | 2 | -34 | -71 | -70 | N/A |
| 12/31/2021 | 13 | -33 | -56 | -55 | N/A |
| 9/30/2021 | 13 | -46 | -46 | -46 | N/A |
| 6/30/2021 | 12 | -45 | -39 | -39 | N/A |
| 3/31/2021 | 12 | -53 | -36 | -36 | N/A |
| 12/31/2020 | N/A | -55 | -49 | -49 | N/A |
| 9/30/2020 | N/A | -27 | -46 | -46 | N/A |
| 6/30/2020 | N/A | -36 | -47 | -47 | N/A |
| 3/31/2020 | 0 | -38 | -46 | -46 | N/A |
| 12/31/2019 | 0 | -54 | -38 | -38 | N/A |
| 9/30/2019 | 0 | -37 | -31 | -31 | N/A |
| 6/30/2019 | 0 | -29 | -27 | -26 | N/A |
| 3/31/2019 | 0 | -31 | -27 | -27 | N/A |
| 12/31/2018 | 0 | -12 | -29 | -28 | N/A |
| 9/30/2018 | 0 | -22 | -28 | -27 | N/A |
| 6/30/2018 | 0 | -31 | N/A | -27 | N/A |
| 3/31/2018 | 0 | -24 | N/A | -26 | N/A |
| 12/31/2017 | 0 | -25 | N/A | -25 | N/A |
| 9/30/2017 | 0 | -21 | N/A | -24 | N/A |
| 6/30/2017 | 0 | -24 | N/A | -26 | N/A |
| 3/31/2017 | 0 | -28 | N/A | -27 | N/A |
| 12/31/2016 | 0 | -30 | N/A | -29 | N/A |
| 9/30/2016 | 0 | -35 | N/A | -31 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -30 | N/A |
| 3/31/2016 | 0 | -30 | N/A | -29 | N/A |
| 12/31/2015 | 0 | -28 | N/A | -25 | N/A |
| 9/30/2015 | 1 | -23 | N/A | -20 | N/A |
| 6/30/2015 | 1 | -19 | N/A | -18 | N/A |
| 3/31/2015 | 1 | -11 | N/A | -14 | N/A |
| 12/31/2014 | 1 | -7 | N/A | -9 | N/A |
| 9/30/2014 | 4 | -42 | N/A | -9 | N/A |
| 6/30/2014 | 8 | -43 | N/A | -6 | N/A |
| 3/31/2014 | 12 | -47 | N/A | -2 | N/A |
| 12/31/2013 | 17 | -47 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 135A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 135A is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 135A is expected to become profitable in the next 3 years.
Revenue vs Market: 135A's revenue (30.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 135A's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 135A's Return on Equity is forecast to be high in 3 years time